Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
death D28 | 1.05 [0.96, 1.15] | | < 1 | | 27% | 21 studies (19/2) | 13.5 % | moderate | low | moderate | crucial | - |
death or transfer to ICU | 0.76 [0.33, 1.79] | | < 1 | | 80% | 2 studies (1/1) | 73.4 % | serious | not evaluable | low | crucial | - |
deaths | 0.82 [0.74, 0.92] | | < 1 | | 68% | 91 studies (71/20) | 100.0 % | moderate | critical | moderate | crucial | - |
deaths (time to event analysis only) | 0.82 [0.69, 0.98] | | < 1 | | 89% | 22 studies (12/10) | 98.7 % | serious | low | low | crucial | - |
clinical deterioration | 0.83 [0.61, 1.14] | | < 1 | | 70% | 19 studies (15/4) | 87.3 % | moderate | low | moderate | important | - |
clinical improvement | 1.15 [1.00, 1.32] | | > 1 | | 44% | 22 studies (20/2) | 97.8 % | moderate | low | moderate | important | - |
clinical improvement (14-day) | 1.07 [0.89, 1.27] | | > 1 | | 48% | 17 studies (17/-) | 76.1 % | some concern | low | moderate | important | - |
clinical improvement (21-day) | 2.09 [0.04, 119.96] | | > 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | important | - |
clinical improvement (28-day) | 1.24 [1.03, 1.50] | | > 1 | | 54% | 9 studies (9/-) | 98.8 % | some concern | not evaluable | moderate | important | - |
clinical improvement (7-day) | 1.15 [0.97, 1.36] | | > 1 | | 45% | 15 studies (14/1) | 94.9 % | moderate | low | moderate | important | - |
clinical improvement (time to event analysis only) | 1.19 [1.08, 1.31] | | > 1 | | 25% | 16 studies (15/1) | 100.0 % | moderate | low | moderate | important | - |
death or ventilation | 1.02 [0.96, 1.09] | | < 1 | | 8% | 9 studies (8/1) | 26.5 % | moderate | not evaluable | moderate | important | - |
hospital discharge | 1.00 [0.94, 1.06] | | > 1 | | 36% | 18 studies (15/3) | 47.4 % | moderate | low | moderate | important | - |
hospitalization | 0.37 [0.26, 0.51] | | < 1 | | 0% | 3 studies (2/1) | 100.0 % | critical | not evaluable | very low | important | - |
mechanical ventilation | 0.90 [0.74, 1.09] | | < 1 | | 31% | 23 studies (22/1) | 85.5 % | moderate | critical | moderate | important | - |
mechanical ventilation (time to event analysis only) | 0.50 [0.13, 1.90] | | < 1 | | 68% | 3 studies (1/2) | 84.5 % | serious | not evaluable | low | important | - |
radiologic improvement (14-day) | 1.17 [0.42, 3.26] | | > 1 | | 16% | 3 studies (3/-) | 62.1 % | some concern | not evaluable | moderate | important | - |
radiologic improvement (7-day) | 0.40 [0.02, 6.97] | | > 1 | | 77% | 3 studies (3/-) | 26.9 % | some concern | not evaluable | moderate | important | - |
viral clearance | 1.29 [0.97, 1.72] | | > 1 | | 66% | 18 studies (16/2) | 96.2 % | moderate | critical | moderate | important | - |
viral clearance (time to event analysis only) | 1.02 [0.83, 1.24] | | > 1 | | 45% | 10 studies (6/4) | 56.0 % | serious | low | low | important | - |
viral clearance by day 14 | 1.33 [0.82, 2.16] | | > 1 | | 62% | 14 studies (10/4) | 87.5 % | serious | low | low | important | - |
viral clearance by day 7 | 1.15 [0.86, 1.54] | | > 1 | | 62% | 11 studies (11/-) | 83.4 % | some concern | low | moderate | important | - |
ICU admission | 0.88 [0.67, 1.16] | | < 1 | | 13% | 13 studies (13/-) | 81.3 % | some concern | low | moderate | non important | - |
off oxygenation | 0.98 [0.64, 1.51] | | > 1 | | 0% | 1 study (1/-) | 46.4 % | NA | not evaluable | | non important | - |
recovery | 1.09 [0.95, 1.26] | | > 1 | | 47% | 5 studies (5/-) | 89.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE leading to drug discontinuation | 2.43 [0.79, 7.45] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | important | - |
cardiac arrest | 1.91 [1.01, 3.62] | | < 1 | | 0% | 2 studies (1/1) | 2.3 % | serious | not evaluable | low | important | - |
related SAE (TRSAE) | 1.24 [0.50, 3.11] | | < 1 | | 0% | 1 study (1/-) | 32.0 % | NA | not evaluable | | important | - |
serious adverse events | 0.85 [0.71, 1.01] | | < 1 | | 0% | 21 studies (21/-) | 96.6 % | some concern | low | moderate | important | - |
abnormal ECG findings | 1.50 [0.88, 2.57] | | < 1 | | 0% | 1 study (-/1) | 7.0 % | NA | not evaluable | | non important | - |
acute kidney injury | 1.18 [0.44, 3.18] | | < 1 | | 0% | 1 study (1/-) | 37.2 % | NA | not evaluable | | non important | - |
adverse events | 1.89 [1.45, 2.47] | | < 1 | | 64% | 22 studies (22/-) | 0.0 % | some concern | critical | moderate | non important | - |
arrhythmia | 1.16 [0.74, 1.80] | | < 1 | | 36% | 4 studies (3/1) | 26.0 % | moderate | not evaluable | moderate | non important | - |
deep vein thrombosis | 0.62 [0.23, 1.64] | | < 1 | | 0% | 2 studies (2/-) | 83.1 % | some concern | not evaluable | moderate | non important | - |
elevated liver enzymes | 0.95 [0.29, 3.10] | | < 1 | | 84% | 3 studies (3/-) | 53.6 % | some concern | not evaluable | moderate | non important | - |
hyperbilirubinemia | 0.97 [0.48, 1.93] | | < 1 | | 0% | 2 studies (2/-) | 53.8 % | low | not evaluable | high | non important | - |
long QT | 2.39 [0.24, 23.87] | | < 1 | | 80% | 2 studies (2/-) | 23.0 % | some concern | not evaluable | moderate | non important | - |
pulmonary embolism | 0.82 [0.20, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 61.1 % | some concern | not evaluable | moderate | non important | - |
renal impairment | 1.26 [0.95, 1.67] | | < 1 | | 0% | 4 studies (4/-) | 5.6 % | some concern | not evaluable | moderate | non important | - |
severe adverse events | 1.10 [0.07, 18.09] | | < 1 | | 0% | 2 studies (2/-) | 47.4 % | high | not evaluable | low | non important | - |
AE of interest endpoints 00 |
Thromboembolic events | 0.89 [0.31, 2.55] | | < 1 | | 0% | 1 study (1/-) | 58.6 % | NA | not evaluable | | non important | - |